N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial
  • Description

    This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life.

    The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions.

    To discuss this data, please contact the NICM Health Research Institute nicm@westernsydney.edu.au.
    • - Start
      Data publication title N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial
    • Description

      This study seeks to elucidate the benefits of NAC augmentation (2-4 grams/day) compared to placebo in the treatment of OCD, in a 24-week, multi-centre, randomized, double-blind, placebo controlled trial. It is hypothesized that NAC will be superior over placebo for improving OCD symptoms as measured by a reduction in Y-BOCS scores from baseline against each subsequent time point (W4, W8, W12, W16, W20 and W24). Additional benefits are anticipated for relieving anxiety as well as improving mood, functioning and overall quality of life.

      The dataset relates to the clinical trial ACTRN12616000847415 N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. This data cannot be shared publicly due to ethics approval conditions.

      To discuss this data, please contact the NICM Health Research Institute nicm@westernsydney.edu.au.
      • Data type dataset
    • Keywords
      • Anxiety
      • Clinical trial
      • Nutraceutical
      • Obsessive compulsive disorder
      • Oxidative stress
      • ACTRN12616000847415
    • Funding source
    • Grant number(s)
      • -
      • FoR codes
      • 420899 - Traditional, complementary and integrative medicine not elsewhere classified
      • 429999 - Other health sciences not elsewhere classified
      SEO codes
      • 200409 - Mental health
      • 200410 - Nutrition
    - Coverage
      Temporal (time) coverage
    • Start date 2017/11/15
    • End date 2020/06/30
      • Time period
       
      Spatial (location,mapping) coverage
    • Locations
      • Australia
    - Data
      Data Locations

      Type Location Notes
      The Data Manager is: Suzannah Bourchier
      Access conditions Restricted
    - Supplements
    - License
      The data will be licensed under
    • Other license
      • Statement of rights in data Copyright Western Sydney University
    - Citation
      Citation Sarris, Jerome; Byrne, Gerard J; Castle, David; Bousman, Chad; Oliver, Georgina; Cribb, Lachlan; Blair-West, Scott; Brakoulias, Vlasios; Camfield, David; Ee, Carolyn; Chamoli, Suneel; Boschen, Mark; Dean, Olivia M; Dowling , Nathan; Menon, Ranjit; Murphy, Jenifer; Metri, Joelle; Nguyen, Thomas P; Wong, Andrew; Jordan, Rebecca; Karamacoska, Diana; Rossell, Susan L; Berk, Michael; Ng, Chee H (2025): N-acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial. Western Sydney University. https://doi.org/10.26183/45ay-r974

    © 2021 Queensland Cyber Infrastructure Foundation